| Project/Area Number |
12670765
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
KUDOH Tooru Sapporo Medical University School of Medicine Associate Professor, 医学部, 助教授 (30117618)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2001: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2000: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | Parvovirus / B19 |
|---|
| Research Abstract |
Human parvovirus B19 (B19) is believed to have only one immunoserotype. We encountered a patient who appeared to have reinfection 3 years after the primary infection. The genome type of B19 DNA obtained from his serum in the primary infection and during the secondary infection was analyzed and compared with those from patients with erythema infectiosum which was prevalent during the same time period. DNA products amplified by long nested PCR were examined. Genome types were analyzed by restrictive endonuclease cleavage pattern. The strain obtained from erythema infectiosum patients changed during the 3 years. There was no difference in genome type between the primary and the secondary infection when serum samples from our patient who seemed to have a reinfection were analyzed and compared. Latent B19 infection may persist after a primary infection. The secondary detection of B19 IgM and DNA was assumed to be due to reactivation after a latent infection.
B19 can be transmitted through blood transfusion and plasma-derived products. We attempted a large-scale screening of B19 in blood products transfused in our hospital from January to May in 1992. Among 3,342 plasma samples kept frozen from packed red blood cells, 22 samples were positive for parvovirus B19 (B19) IgM by enzyme immunoassay. Of these 22 samples, 11 (0.33%) were positive for both B19 IgG and B19 DNA by polymerase chain reaction indicating contamination with B19. The incidence was obviously higher than in those (0.012%) tested by the receptor-mediated haemagglutination assay considered as a sensitive method. The findings suggest that the method reported has enough sensitivity and specificity to detect B19 in human plasma and its use might help prevent transfusion mediated viral infection in those susceptible such as immunocompromised patients or pregnant women.
|
